By Amy Orciari Herman
Edited by André Sofair, MD, MPH
High-risk patients who undergo percutaneous coronary intervention (PCI) and take dual antiplatelet therapy may fare better if they discontinue the aspirin after 3 months, according to an industry-supported trial. The findings were presented at the 2019 Transcatheter Cardiovascular Therapeutics conference and published in the New England Journal of Medicine.
Over 7000 high-risk patients who completed 3 months of ticagrelor plus aspirin after PCI were randomized to continue ticagrelor plus aspirin or to replace aspirin with placebo for 1 year. From randomization to 1 year, the incidence of clinically significant bleeding was lower among patients taking ticagrelor plus placebo than among those who continued aspirin (4% vs. 7%). This benefit did not occur at the expense of more cardiovascular events with placebo.